#ASCO2022 – Estudo randomizado | Análise do DNA circulante de tumor como orientação para terapia adjuvante no câncer de cólon estágio II.

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comunicado de imprensa: DNA shed from colon cancers into bloodstream successfully guides chemotherapy after surgery – Helps clarify the benefit of chemotherapy in stage II cancers – Johns Hopkins Medicine

Comentário: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network

Comentário no Twitter

DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 pic.twitter.com/gvHMnGWbyE

— NEJM (@NEJM) June 4, 2022